<DOC>
	<DOCNO>NCT01303094</DOCNO>
	<brief_summary>This randomization discontinuation trial allow concomitant evaluation following : - Side effect benefit immediate continuation Trabectedin sixth cycle - Side effect benefit drug holiday</brief_summary>
	<brief_title>Continuing vs Intermittent Trabectedin Patients With Advanced Soft Tissue Sarcoma</brief_title>
	<detailed_description>Selection part ( 220 patient ) : Trabectedin ( depend dose reduction : 1.5 1 mg/m²/3 week ; 24 hour administration ) progression , intolerance 6 cycle ( accord SPC Trabectedin ) Randomized part ( 50 patient ) : After 6 first cycle , progression unacceptable toxicity , patient randomly assign continuous `` intermittent/holiday '' therapy CT-scan evaluation every 6 week arm - Arm A Continuation Trabectedin ( 1.5 1 mg/m²/3 week ; 24 hour administration ) progression intolerance - Arm B `` Intermittent/holiday '' therapy . Rechallenge Trabectedin implement event progression ; case administration Trabectedin occur second progression intolerance</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Trabectedin</mesh_term>
	<criteria>Inclusion Criteria ( selection part ) : Inoperable metastatic soft tissue sarcoma and/or uterine sarcoma Measurable lesion ( RECIST 1.1 ) Performance status ≤ 2 Age ≥ 18 Normal hematological parameter ( polynuclear neutrophil ≥ 1500 , hemoglobin level ≥ 9 g/dl , platelets count ≥ 100,000 ) Adequate biological parameter : Adequate hepatic function ( bilirubin ≤ ULN , SGPT/ALT SGOT/AST ≤ 2.5 x ULN ) Alkaline phosphatases ≤ 2.5 x ULN , If Alkaline phosphatases ≥ 2.5 ULN , hepatic isoenzymes 5nucleotidases GGT test must perform ; hepatic isoenzymes 5 nucleotidases and/or GGT must within normal range Albumin ≥ 25 g/L Adequate renal function : Serum creatinine ≤ 1.5 x ULN Creatine phosphokinase ≤ 2.5 x ULN Adequate central venous access Pregnant lactate woman men reproductive potential must use effective contraceptive method Patient cover government health insurance Information sheet give patient ( Patient information sheet 1 ) Exclusion Criteria ( selection part ) : Patients receive one regimen chemotherapy metastatic inoperable soft tissue uterine sarcoma , failure/intolerance doxorubicin ifosfamide . Maintenance treatment count treatment line The following histological subtypes : GIST , rhabdomyosarcoma , aggressive fibromatosis , desmoïd tumour , PNET , carcinosarcoma , bone sarcoma Single tumour irradiate region Other malignant tumour past five year ( except basal cell carcinoma cervical carcinoma situ adequately treat ) Currently active bacterial fungus infection ( &gt; grade 2 CTC [ CTCAE ] Version 4.02 ) . Known HIV1 , HIV2 , hepatitis B hepatitis C infection Presence know leptomeningeal brain metastasis Patients unable receive corticotherapy Any circumstance could jeopardise compliance proper followup trial Pregnant nursing woman Inclusion Criteria ( randomize part ) : Patient register selection part Stable tumour objective response ( CR + PR ) 6 Trabectedin ( Yondelis® ) cycle , accord local assessment Available copy thoracoabdominal pelvic scan perform prior first cycle sixth cycle Performance status ≤ 2 Patients receive least 1 mg/m²/3 week Trabectedin time sixth cycle Normal hematological parameter ( polynuclear neutrophil ≥ 1500 , hemoglobin level ≥ 9 g/dl , platelets count ≥ 100,000 ) Adequate biological parameter : Adequate hepatic function ( bilirubin ≤ ULN , SGPT/ALT SGOT/AST ≤ 2.5 x ULN ) Alkaline phosphatases ≤ 2.5 x ULN , If Alkaline phosphatases ≥ 2.5 ULN , hepatic isoenzymes 5nucleotidases GGT test must perform ; hepatic isoenzymes 5 nucleotidases and/or GGT must within normal range Albumin ≥ 25 g/L Adequate renal function : Serum creatinine ≤ 1.5 x ULN Creatine phosphokinase ( CPK ) ≤ 2.5 x ULN Adequate central venous access Pregnant lactate woman men reproductive potential must use effective contraceptive method Informed consent form sign patient patient 's legal representative ( patient information sheet 2 informed consent ) Exclusion Criteria ( randomize part ) : Tumour progression ( accord RECIST 1.1 ) first six Yondelis cycle Nonavailability baseline scan prior first cycle follow sixth cycle Currently active bacterial fungus infection ( &gt; grade 2 CTC [ CTCAE ] Version 4.02 ) . Known HIV1 , HIV2 , hepatitis B hepatitis C infection Presence know leptomeningeal brain metastasis Creatinine clearance le 30 ml/min Patients unable receive corticotherapy Any circumstance could jeopardise compliance proper followup trial Pregnant nursing woman Hypersensitivity Trabectedin excipient prior cycle</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>